Premas Biotech reports positive preliminary phase-1 data for oral COVID vaccine, developed for Oravax Medical

Preliminary Phase 1 trial results from the first cohort include:

• Significant antibody response (2-6 fold over baseline) as measured by multiple markers of immune response to VLP vaccine antigens observed in the majority of the patients dosed
• was observed in 75% of the patients dosed
• No safety issues were observed, including mild symptoms

Oravax Medical is a clinical-stage vaccine company developing oral vaccines that combine Premas Biotech's D-Crypt Platform with Oramed Pharmaceuticals' POD technology. Oravax's oral Covid-19 vaccine candidate is designed using D-Crypt technology as a triple antigen VLP vaccine that targets three major surface proteins of the SARS-CoV-2 virus - Spike, Membrane and Envelope. This should allow the oral vaccine candidate to trigger a protective response not only against the prevalent strains of the SARS-CoV-2 virus but also the emerging mutations.

Read also: Premas Biotech, Oramed Pharma together to develop oral COVID-19 vaccine effective after single dose

"We're very encouraged by this initial data, which indicates that our platform can be safely and successfully used to orally deliver protein-based vaccines," said Nadav Kidron, Chairman of Oravax and CEO of Oramed Pharmaceuticals.

"These results, together with the recent evolution of the Covid strains, further raise our confidence in the success of an oral Covid-19 vaccine and the broad potential of our platform along with Oramed's POD platform to explore oral vaccines for other infectious diseases," said Dr Prabuddha Kundu, Co-founder and Managing Director, Premas Biotech.

Premas Biotech develops novel technologies & bioprocesses and partners with global biopharmaceutical companies to build and develop novel biotherapeutic & vaccine candidates. Premas' key focus areas are infectious diseases, cancer, metabolic disorders and inflammation.